Bending the cost curve in cancer care

New England Journal of Medicine

Volumn 364, Issue 21, 2011, Pages 2060-2065

  Smith, Thomas J ^a,b   Hillner, Bruce E ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; COLONY STIMULATING FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IXABEPILONE; TRASTUZUMAB;

ARTIFICIAL VENTILATION; BREAST CANCER; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; COGNITION; COLON CANCER; COMBINATION CHEMOTHERAPY; COMPENSATION; COMPUTER ASSISTED TOMOGRAPHY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; FEBRILE NEUTROPENIA; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH STATUS; HOSPITALIZATION; HUMAN; INFORMED CONSENT; INTEGRATION; INTENSIVE CARE; LIVER METASTASIS; LUNG SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); METASTASIS POTENTIAL; MONOTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PATIENT COUNSELING; PATIENT SATISFACTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SELF CARE; SYSTEMATIC REVIEW; TERMINAL CARE; TREATMENT RESPONSE;

EID: 79957492218     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMsb1013826     Document Type: Review

References (64)

1. National Cancer Institute. Cancer trends progress report - 2009/2010 update. (http://progressreport.cancer.gov/doc-detail.asp?pid=1&did= 2009&chid=95&coid=926&mid=.)
2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28.
3. Elkin EB, Bach PB. Cancer's next frontier: addressing high and increasing costs. JAMA 2010;303:1086-7.
4. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst 2008;100:630-41.
5. Fojo T, Grady C. How much is life worth: cetuximab, nonsmall cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009;101:1044-8.
6. Hillner BE, Smith TJ. Efficacy does not necessarily translate to cost effectiveness: a case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 2009;27:2111-3.
7. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009;360:626-33.
8. Aaron HJ, Ginsburg PB. Is health spending excessive? If so, what can we do about it? Health Aff (Millwood) 2009;28:1260-75.
9. Brody H. Medicine's ethical responsibility for health care reform - the Top Five list. N Engl J Med 2010;362:283-5.
10. Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer followup and management guidelines in the adjuvant setting. J Clin Oncol 2006;24:5091-7.
11. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer: clinical practice guidelines in oncology. J Natl Compr Canc Netw 2009;7:122-92.
12. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 2010;376:1155-63.
13. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66.
14. Schapira DV, Urban N. A minimalist policy for breast cancer surveillance. JAMA 1991;265:380-2.
15. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
16. Loprinzi CL, Hayes D, Smith T. Doc, shouldn't we be getting some tests? J Clin Oncol 2003;21:Suppl:108s-111s.
17. Smith TJ. The American Society of Clinical Oncology Recommended Breast Cancer Surveillance Guidelines can be done in a routine office visit. J Clin Oncol 2005;23:6807. (Pubitemid 46190290)
18. Jacobson JO, Neuss MN, McNiff KK, et al. Improvement in oncology practice performance through voluntary participation in the Quality Oncology Practice Initiative. J Clin Oncol 2008;26:1893-8.
19. Cardoso F, Bedard PL, Winer EP, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009;101:1174-81.
20. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009;2:CD003372.
21. Smith TJ, Hillner BE. Comment on pegylated liposomal doxorubicin plus docetaxel in metastatic breast cancer. J Clin Oncol 2010;28(8):e128.
22. Eastern Cooperative Oncology Group. ECOG performance status. (http://ecog.dfci.harvard.edu/general/perf-stat.html.)
23. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205. (Pubitemid 46638957)
24. Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2008;4:CD003189.
25. Kelly K. First-line chemotherapy for small cell lung cancer. Waltham, MA: Up To Date, January 2011.
26. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67. (Pubitemid 47218066)
27. Timmer-Bonte JN, Adang EM, Termeer E, Severens JL, Tjan-Heijnen VC. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. J Clin Oncol 2008;26:290-6.
28. Brickates Kennedy V. Amgen reports lower profit, flat sales. MarketWatch. October 25, 2010. (http://www.marketwatch.com/story/amgen-reports-lower-profit- flat-sales-2010-10-25-1926100.)
29. Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2010;8:740-801.
30. Peppercorn JM, Smith TJ, Helft PR, et al. American Society of Clinical Oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol 2011;29:755-60.
31. Dow L, Matsuyama RK, Ramakrishnan V, et al. Paradoxes in advance care planning: the complex relationship of oncology patients, their physicians, and advance medical directives. J Clin Oncol 2010;28:299-304.
32. Wright AA, Zhang B, Ray A, et al. Associations between endof- life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. JAMA 2008;300:1665-73.
33. Keating NL, Landrum MB, Rogers SO Jr, et al. Physician factors associated with discussions about end-of-life care. Cancer 2010;116:998-1006.
34. Huskamp HA, Keating NL, Malin JL, et al. Discussions with physicians about hospice among patients with metastatic lung cancer. Arch Intern Med 2009;169:954-62.
35. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-42.
36. Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med 2009;169:480-8.
37. Donovan RJ, Carter OB, Byrne MJ. People's perceptions of cancer survivability: implications for oncologists. Lancet Oncol 2006;7:668-75. (Pubitemid 44137112)
38. Smith TJ, Hillner BE. Concrete options and ideas for increasing value in oncology care: the view from one trench. Oncologist 2010;15:Suppl 1:65-72.
39. Sepucha KR, Ozanne EM, Partridge AH, Moy B. Is there a role for decision aids in advanced breast cancer? Med Decis Making 2009;29:475-82.
40. Chiew KS, Shepherd H, Vardy J, Tattersall MH, Butow PN, Leighl NB. Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer. Health Expect 2008;11:35-45. (Pubitemid 351239418)
41. Smith TJ, Dow LA, Virago E, Khatcheressian J, Matsuyama RM. A pilot trial of truthful decision aids for patients with metastatic advanced cancer. J Support Oncol 2011;9:79-86.
42. Smith TJ, Dow LA, Virago E, Khatcheressian J, Lyckholm LJ, Matsuyama R. Giving honest information to patients with advanced cancer maintains hope. Oncology 2010;24:521-5.
43. Jackson VA, Mack J, Matsuyama R, et al. A qualitative study of oncologists' approaches to end-of-life care. J Palliat Med 2008;11:893-906.
44. American Society of Clinical Oncology Outcomes Working Group. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-9.
45. Bodenheimer T, Berenson RA, Rudolf P. The primary carespecialty income gap: why it matters. Ann Intern Med 2007;146:301-6. (Pubitemid 351650616)
46. Jacobson M, O'Malley AJ, Earle CC, Pakes J, Gaccione P, Newhouse JP. Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) 2006;25:437-43.
47. Jacobson M, Earle CC, Price M, Newhouse JP. How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood) 2010;29:1391-9.
48. Neubauer MA, Hoverman JR, Kolodziej M, et al. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract 2010;6:12-8.
49. Johnson A. In treating cancer, insurer tries new way to pay docs. Wall Street Journal. October 19, 2010.
50. Hortobagyi GN. A shortage of oncologists? The American Society of Clinical Oncology workforce study. J Clin Oncol 2007; 25:1468-9. (Pubitemid 46733072)
51. Finn JW, Pienta KJ, Parzuchowski J, Worden F. Bridging cancer treatment and hospice care. Proc Am Soc Clin Oncol 2002;21:1452. abstract.
52. Gade G, Venohr I, Conner D, et al. Impact of an inpatient palliative care team: a randomized control trial. J Palliat Med 2008;11:180-90. (Pubitemid 351374198)
53. Brumley R, Enguidanos S, Jamison P, et al. Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc 2007;55:993-1000. (Pubitemid 47024627)
54. Spettell CM, Rawlins WS, Krakauer R, et al. A comprehensive case management program to improve palliative care. J Palliat Med 2009;12:827-32.
55. The Dartmouth Atlas of Health Care home page. (http://www.dartmouthatlas. org.)
56. Connor SR, Pyenson B, Fitch K, Spence C, Iwasaki K. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007;33:238-46. (Pubitemid 46349540)
57. Pyenson B, Connor S, Fitch K, Kinzbrunner B. Medicare cost in matched hospice and non-hospice cohorts. J Pain Symptom Manage 2004;28:200-10. (Pubitemid 39158802)
58. Harrington SE, Smith TJ. The role of chemotherapy at the end of life: "when is enough, enough?" JAMA 2008;299:2667-78.
59. Blayney DW, McNiff K, Hanauer D, Miela G, Markstrom D, Neuss M. Implementation of the Quality Oncology Practice Initiative at a university comprehensive cancer center. J Clin Oncol 2009;27:3802-7.
60. Smith TJ, Bodurtha JN. Ethical considerations in oncology: balancing the interests of patients, oncologists, and society. J Clin Oncol 1995;13:2464-70.
61. Levy AR, Mitton C, Johnston KM, Harrigan B, Briggs AH. International comparison of comparative effectiveness research in five jurisdictions: insights for the US. Pharmacoeconomics 2010;28:813-30.
62. Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009;302:1437-43.
63. Pearson SD, Bach PB. How Medicare could use comparative effectiveness research in deciding on new coverage and reimbursement. Health Aff (Millwood) 2010;29:1796-804.
64. Matsuyama R, Reddy SN, Smith TJ. Why do patients choose chemotherapy near the end of life? J Clin Oncol 2006;24:3490-6.